Noah Labs receives €3 million in financing round lead by Nina Capital
Noah Labs Ark, the company's flagship software, which received approval as a Class IIa medical device under the EU Medical Device Regulation (MDR) in April, enables comprehensive remote monitoring and management of chronic diseases. Doctors can detect deterioration and risks early, which has been shown to reduce cardiovascular complications, hospitalizations, and mortality, such as in cases of heart failure. To achieve this, Noah Labs Ark monitors relevant vital parameters to assess and predict patient health. The current focus of the cardiological application is heart failure, but the software also monitors hypertension and cardiac arrhythmias. Smartwatches, ECGs, and blood pressure monitors, which are approved as medical devices, transmit the data collected from patients in real-time to the practice or clinic.
Another current research focus of Noah Labs is the development and application of AI in voice-based diagnostics of heart diseases. The company has entered into a strategic partnership with the German Heart Center of the Charité (DHZC) in Berlin. As part of a clinical study, project partners, including the Mayo Clinic in the USA, are investigating the effectiveness and potential of voice analysis as a novel, non-invasive, and early biomarker for the diagnosis and monitoring of patients with heart failure. Noah Labs' AI analyzes hundreds of parameters in the voice samples of the study participants, capturing even the smallest changes. In the long term, such a solution can help to identify changes at an early stage and thus make timely therapeutic decisions to effectively reduce hospital stays.
Noah Labs co-founder and CEO Oliver Piepenstock said, "We are proud that our high-caliber investors share our vision, which is ‘Live healthier for longer with AI-driven Care and Research’. We were eager to work together with true health tech experts who, in addition to capital, bring their expertise and networks as healthcare entrepreneurs, regulatory experts, and healthcare systems. We are especially pleased to be the first external investment of the DHZB Foundation. With the fresh capital, we will further intensify our research activities in voice analysis and develop our solutions for other medical conditions in the long term."
Marta Zanchi, founder and managing partner of Nina Capital, commented, "We were particularly impressed by Noah Labs' research-centric approach. The team is constantly exploring new possibilities and pushing the boundaries of what is possible to significantly improve the quality of life for chronic heart patients. The associated technology-driven process is absolutely convincing and makes an important pioneering contribution to scientific research. Noah Labs puts people at the center of its work, developing software and products that are intuitive, user-friendly, and accessible to everyone."
Andreas Portmann, Managing Director of the DHZB Foundation, states: "Our foundation aims to significantly improve the lives of people with cardiovascular diseases and to prevent these conditions in the future. To achieve this, we specifically support innovative projects that modernize our healthcare system and add value for patients. We are convinced that digital tools and novel voice-based biomarkers will offer a decisive advantage in cardiovascular medicine. Noah Labs has developed an exceptional technology platform for this purpose and is part of an outstanding innovation ecosystem in Berlin that truly impacts patients."
Malte Unger, Managing Partner of adesso ventures: “Noah Labs is setting new standards in the industry with its innovative AI-based voice analysis for the detection of heart failure. Together with the already successfully implemented Ark platform, the company offers a comprehensive solution to support patients with chronic heart conditions. As a tech investor with a focus on ambitious ventures, we were particularly impressed by the technological maturity and expertise of the founding team.”
